Recent Updates
Recently added Catalysts
BRKR Positive Sentiment

Bruker Advances Functional Proteomics with Novel timsUltra AIP and timsOmni Workflows for Drug Discovery & Development and Disease Biology Research

Monday, September 28, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Bruker Corporation has unveiled new timsUltra AIP and timsOmni workflows at the Human Proteome Organization World Congress 2026. These workflows aim to enhance protein-sequence coverage and facilitate targeted validation, mobility-resolved glycopeptide characterization, and structural proteomics. The introduction of multi-enzyme dia-PASEF is expected to provide additional peptide information, advancing research in drug discovery and disease biology.

Market Sentiment Analysis

POSITIVE FACTORS

  • Introduction of innovative timsUltra AIP and timsOmni workflows.
  • Enhanced protein-sequence coverage and targeted validation.
  • Improved glycopeptide characterization and structural proteomics.
  • Potential for deeper insights in drug discovery and disease biology.

Full Press Release Details

SINGAPORE--(BUSINESS WIRE)---- $BRKR #BRKR--At the Human Proteome Organization World Congress 2026, Bruker Corporation (Nasdaq: BRKR) today announced unique new timsUltra AIP and timsOmni workflows for deeper protein-sequence coverage, targeted validation, mobility-resolved glycopeptide characterization, structural proteomics, and oligonucleotide analysis. Multi-enzyme dia-PASEF provides additional peptide information for investigations of isoforms and proteoforms, while ProteoScape workflows connect PASEF dis

Frequently Asked Questions

What are the new workflows introduced by Bruker?

Bruker introduced the timsUltra AIP and timsOmni workflows for enhanced proteomics.

What is the purpose of the new workflows?

These workflows aim to improve protein-sequence coverage and targeted validation.

Where was the announcement made?

The announcement was made at the Human Proteome Organization World Congress 2026.

What additional information does multi-enzyme dia-PASEF provide?

It provides additional peptide information for studying isoforms and proteoforms.

ShareAdd on Google
Tags: BRKR Viatris Investor Conferences Healthcare Bruker timsUltra proteomics drug discovery glycopeptide characterization
Last updated: Sep 28, 2026

Biotech snapshot

Cash runway
$185M liquidity · $26M/mo burn
~6 mo
High dilution risk